Global Pharma on the Move — Deal Highlights :February 2026

Strategic collaborations, acquisitions, and technology alliances continued to reshape the pharmaceutical and life sciences ecosystem in February 2026. Companies across the drug discovery, diagnostics, manufacturing, and digital health landscape pursued partnerships to expand technological capabilities, strengthen research pipelines, and accelerate commercialization pathways. Several deals focused on high-growth segments such as antibody–drug conjugates (ADCs), metabolic disease therapies, AI-driven drug discovery, and cell and gene therapy manufacturing, underscoring the industry’s shift toward advanced therapeutics and precision medicine.

AI, Bioconjugates and Oncology Take Center Stage

One of the key strategic collaborations announced during the month involved Earendil Labs partnering with WuXi XDC Cayman Inc. to advance next-generation antibody–drug conjugates (ADCs). The agreement grants Earendil an exclusive global license to WuXi XDC’s proprietary WuXiTecan-2 payload-linker technology for use against multiple targets. By combining Earendil’s AI-driven antibody discovery platform with WuXi XDC’s bioconjugation technologies, the companies aim to accelerate the development of targeted oncology therapies addressing significant unmet

Another oncology-focused alliance emerged between Astellas Pharma Inc. and Vir Biotechnology. The companies entered a global collaboration to advance VIR-5500, an investigational dual-masked CD3 T-cell engager targeting PSMA for prostate cancer treatment. By combining Astellas’ deep expertise in prostate cancer with Vir’s PRO-XTEN technology platform, the collaboration aims to accelerate the development of potentially best-in-class immunotherapies for solid tumors.

The partnership reinforces Astellas’ strategic focus on expanding its immuno-oncology pipeline while leveraging innovative biotechnology platforms through external collaborations.

Metabolic Disease Partnerships Gain Momentum

The rapidly growing metabolic disease and obesity therapeutics market also witnessed significant deal activity in February. Hangzhou-based Sciwind Biosciences signed a strategic commercialization agreement with Pfizer China for Ecnoglutide, a next-generation GLP-1 receptor agonist developed by Sciwind.

Under the agreement, Pfizer will obtain exclusive commercialization rights for the therapy in mainland China while Sciwind retains responsibility for development, manufacturing, and supply. The deal could generate up to $495 million in upfront and milestone payments for Sciwind.

The partnership reflects the intense global competition among pharmaceutical companies to secure innovative therapies targeting obesity and metabolic disorders—an area expected to generate multi-billion-dollar market opportunities in the coming decade.

Manufacturing Partnerships Strengthen Supply Chains

Pharmaceutical manufacturing and contract development organizations also played a major role in February’s deal landscape. Bora Pharmaceuticals renewed and expanded its five-year global manufacturing partnership with GSK, a collaboration valued at approximately $250 million.

The agreement reinforces Bora’s role as a key manufacturing partner for GSK and expands access to Bora’s global production network, including its new oral solid dose facility in Maple Grove, Minnesota. At Bora’s Mississauga facility, the company currently manufactures more than 20 commercial product lines and over 335 individual products for GSK across multiple therapeutic areas including HIV, malaria, migraine, eczema, and psoriasis.

Similarly, Scinai Immunotherapeutics strengthened its CDMO platform through the acquisition of Recipharm Israel Ltd., which operates a cGMP manufacturing facility in Yavne, Israel. The deal expands Scinai’s capabilities in early chemistry development and small-scale manufacturing of active pharmaceutical ingredients (APIs).

Alongside the acquisition, Scinai and Recipharm entered a long-term collaboration designed to streamline technology transfer and support clients transitioning from early development to late-stage clinical and commercial manufacturing.

Major M&A Moves Reshape Diagnostics and Life Sciences

Several large acquisitions also took place in February, reflecting ongoing consolidation across diagnostics and life sciences tools markets.

Danaher Corporation announced a definitive agreement to acquire Masimo Corporation, in a transaction valued at approximately $9.9 billion. The acquisition is expected to strengthen Danaher’s diagnostics franchise by integrating Masimo’s monitoring technologies into its global life sciences and healthcare portfolio.

Danaher plans to leverage its Danaher Business System and global commercial infrastructure to expand Masimo’s reach in acute care settings while driving innovation in patient monitoring technologies.

In another significant portfolio realignment, BD completed the spin-off of its Biosciences and Diagnostic Solutions business and combined it with Waters Corporation. The transaction valued the business at $18.8 billion and resulted in BD shareholders owning approximately 39.2 percent of the combined company.

The move represents the final milestone in BD’s long-term strategic transformation plan aimed at focusing the company on core medical technology segments while unlocking value from its diagnostics business.

Strategic Collaborations Accelerate Drug Discovery

Drug discovery partnerships continued to expand across the industry as companies sought to combine complementary capabilities and accelerate R&D pipelines.

Insilico Medicine announced a series of AI-powered drug discovery collaborations with China Medical System Holdings (CMS) to advance multiple therapeutic programs in central nervous system and autoimmune diseases. Under the partnership, Insilico will utilize its Pharma.AI platform for target identification and molecule design, while CMS will contribute expertise in clinical development and commercialization.

The collaboration framework aims to shorten development timelines and improve clinical success rates by integrating AI-driven discovery technologies with established pharmaceutical development capabilities.

Meanwhile, the Jackson Laboratory–New York Stem Cell Foundation Collaborative entered a five-year research partnership with GSK to develop advanced human cellular models for neurodegenerative diseases such as Alzheimer’s disease. The collaboration combines stem cell technologies, large-scale research systems, and translational science to generate more predictive disease models for drug discovery.

The initiative aims to bridge the long-standing gap between early-stage scientific discovery and the development of effective therapies for complex neurological conditions.

Expanding Platforms for Cell and Gene Therapy

The rapidly evolving cell and gene therapy sector also saw several partnerships aimed at expanding manufacturing capabilities and enabling next-generation therapeutic development.

BioLife Solutions signed a multi-year supply agreement with Qkine Limited to distribute cytokine and growth factor products used in cell and gene therapy manufacturing. The partnership provides BioLife with exclusive worldwide distribution rights for specific Qkine products and includes collaboration on process development and validation using BioLife’s proprietary CellSeal Connect vial technology.

At the same time, Cellares announced plans to establish a new integrated development and manufacturing organization (IDMO) facility at Leiden Bio Science Park in the Netherlands. The facility will serve as the company’s European headquarters and provide automated manufacturing infrastructure for cell therapy developers in the region.

The move reflects the growing importance of regional manufacturing capacity in supporting patient-specific therapies such as CAR-T treatments.

Expanding Diagnostic and Life Science Capabilities

The diagnostics and life sciences tools sector also witnessed a series of technology partnerships and acquisitions aimed at expanding capabilities in research and clinical testing.

QuidelOrtho entered a long-term supply agreement with Lifotronic Technology to expand its global immunoassay portfolio. The partnership will provide access to new analyzer platforms and more than 25 additional assays, enabling the company to compete more effectively in laboratory testing markets outside the United States.

SSI Diagnostica Group strengthened its life sciences portfolio through the acquisition of US-based multiplexing technology provider InDevR. The addition enhances the company’s capabilities in vaccine testing and quality control, particularly in influenza and mRNA vaccine development.

Meanwhile, Agilent Technologies expanded its collaboration with Virscidian to integrate the OpenLab CDS platform with Analytical Studio software, enabling scientists to automate complex chromatography and purification workflows in pharmaceutical R&D.

Emerging Innovation Areas

Beyond traditional pharmaceutical partnerships, several deals highlighted emerging areas of innovation within the life sciences sector.

Azenta announced a partnership with Frontier Space to conduct life sciences research experiments in microgravity, leveraging space-based research platforms to accelerate biological discoveries that are difficult to replicate on Earth.

Elsewhere, technology provider OPTEL partnered with Techno Service to deliver localized pharmaceutical track-and-trace solutions in Egypt, helping manufacturers comply with new serialization regulations set by the Egyptian Drug Authority.

Nanologica also strengthened its manufacturing capabilities through the acquisition of Ardena Södertälje AB, expanding its contract development and manufacturing operations in Sweden.

Outlook

February’s deal activity underscores several key trends shaping the pharmaceutical industry. Companies are increasingly leveraging strategic partnerships to access advanced technologies such as artificial intelligence, bioconjugation platforms, and stem cell models. At the same time, acquisitions and manufacturing alliances continue to strengthen global supply chains and expand production capacity for complex biologics and cell therapies.

With growing competition in areas such as metabolic disease, oncology, and gene therapy, collaborations between biotechnology innovators and established pharmaceutical companies are expected to remain a central driver of industry growth throughout 2026.